Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ABTL 0812

Next Previous
Drug Profile

ABTL 0812

Alternative Names: ABTL-0812; LAM-182; LP-10218; SCLN-0812

Latest Information Update: 28 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lipopharma
  • Developer Ability Pharmaceuticals; SciClone Pharmaceuticals
  • Class Antineoplastics; Small molecules; Unsaturated fatty acids
  • Mechanism of Action Autophagy stimulants; Peroxisome proliferator-activated receptor alpha agonists; Peroxisome proliferator-activated receptor gamma agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Biliary cancer; Pancreatic cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes - Pancreatic cancer

Highest Development Phases

  • Phase II Endometrial cancer; Pancreatic cancer; Squamous cell cancer
  • Preclinical Non-small cell lung cancer
  • No development reported Biliary cancer; Neuroblastoma; Solid tumours

Most Recent Events

  • 15 Mar 2024 Ability Pharmaceuticals completes the phase I/II PanC-ASAP trial in Pancreatic cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA, France, Israel, Spain (PO) (NCT04431258) (EudraCT2020-002791-13)
  • 11 Mar 2024 Ability Pharmaceuticals plans to launch ABTL 0812 for Pancreatic Cancer in 2028
  • 28 Jul 2023 No recent reports of development identified for preclinical development in Biliary-cancer in Spain (PO, Liquid)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top